Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.

Journal Article (Journal Article)

BACKGROUND: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and without prior intravesical Bacillus Calmette-Guerin (BCG), who received ICI for aUC, hypothesizing that prior intravesical BCG would be associated with worse outcomes. PATIENTS AND METHODS: We performed a retrospective cohort study across 25 institutions in US and Europe. We compared observed response rate (ORR) using logistic regression; progression-free survival (PFS) and OS using Kaplan-Meier and Cox proportional hazards. Analyses were stratified by treatment line (first line/salvage) and included multivariable models adjusting for known prognostic factors. RESULTS: A total of 1026 patients with aUC were identified; 614, 617, and 638 were included in ORR, OS, PFS analyses, respectively. Overall, 150 pts had history of prior intravesical BCG treatment. ORR to ICI was similar between those with and without prior intravesical BCG exposure in both first line and salvage settings (adjusted odds radios 0.55 [P= .08] and 1.65 [P= .12]). OS (adjusted hazard ratios 1.05 [P= .79] and 1.13 [P= .49]) and PFS (adjusted hazard ratios 1.12 [P= .55] and 0.87 [P= .39]) were similar between those with and without intravesical BCG exposure in first line and salvage settings. CONCLUSION: Prior intravesical BCG was not associated with differences in response and survival in patients with aUC treated with ICI. Limitations include retrospective nature, lack of randomization, presence of selection and confounding biases. This study provides important preliminary data that prior intravesical BCG exposure may not impact ICI efficacy in aUC.

Full Text

Duke Authors

Cited Authors

  • Talukder, R; Makrakis, D; Diamantopoulos, LN; Carril-Ajuria, L; Castellano, D; De Kouchkovsky, I; Koshkin, VS; Park, JJ; Alva, A; Bilen, MA; Stewart, TF; McKay, RR; Santos, VS; Agarwal, N; Jain, J; Zakharia, Y; Morales-Barrera, R; Devitt, ME; Grant, M; Lythgoe, MP; Pinato, DJ; Nelson, A; Hoimes, CJ; Shreck, E; Gartrell, BA; Sankin, A; Tripathi, A; Zakopoulou, R; Bamias, A; Murgic, J; Fröbe, A; Rodriguez-Vida, A; Drakaki, A; Liu, S; Kumar, V; Lorenzo, GD; Joshi, M; Velho, PI; Buznego, LA; Duran, I; Moses, M; Barata, P; Sonpavde, G; Yu, EY; Wright, JL; Grivas, P; Khaki, AR

Published Date

  • April 2022

Published In

Volume / Issue

  • 20 / 2

Start / End Page

  • 165 - 175

PubMed ID

  • 35078711

Pubmed Central ID

  • PMC8995351

Electronic International Standard Serial Number (EISSN)

  • 1938-0682

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2021.12.012


  • eng

Conference Location

  • United States